var path='https://www.tickertech.net'; function heading(heading) { document.write('

'+ ''+ '
• '+heading+'
'+ ''+ '

'); } function hiLite(imgDocID,imgObjName) { document.images[imgDocID].src = eval(imgObjName + ".src"); } function showStatus(toshow) { window.status = toshow; } function checkChoose() { if (document.choose.ticker.value == "") { alert("Please enter symbols before clicking the go button"); return false; } else return true; } function popJT(url,name){ var xwid = screen.width; xwid = xwid - 10; javaticker = window.open(url,name,'width='+xwid+',height=100,resizable=yes,scrollbars=no,toolbar=no,location=no,directories=no,status=yes,menubar=no'); javaticker.opener.name="opener"; //javaticker.moveTo(0,30); } var allow = 0; var ref = ""+location; if ((ref.indexOf("cryptocurrencieschannel.com") > 0) || (ref.indexOf("cefchannel.com") > 0) || (ref.indexOf("bdcinvestor.com") > 0) || (ref.indexOf("tickertech.com") > 0) || (ref.indexOf("xxxx:") > 0) || (ref.indexOf("javascript:") > 0) || (ref.indexOf("filseclab.com") > 0) || (ref.indexOf("msnscache.com") > 0) || (ref.indexOf("toolbar.google.com") > 0) || (ref.indexOf("etfchannel.com") > 0) || (ref.indexOf("marketnewsvideo.com") > 0) || (ref.indexOf("news.google.com") > 0) || (ref.indexOf("dividendchannel.com") > 0) || (ref.indexOf("www.google.com") > 0) || (ref.indexOf("energystockchannel.com") > 0) || (ref.indexOf("metalschannel.com") > 0) || (ref.indexOf("portfoliochannel.com") > 0) || (ref.indexOf("canadastockchannel.com") > 0) || (ref.indexOf("theonlineinvestor.com") > 0) || (ref.indexOf("investhelp.com") > 0) || (ref.indexOf("preferredstockchannel.com") > 0) || (ref.indexOf("stockoptionschannel.com") > 0) || (ref.indexOf("holdingschannel.com") > 0) || (ref.indexOf("tickertech.net") > 0) || (ref.indexOf("historicalstockprice.com") > 0) || (ref.indexOf("splithistory.com") > 0) || (ref.indexOf("stocksplithistory.com") > 0) || (ref.indexOf("google.c") > 0) || (ref.indexOf("208.71.46.190") > 0) || (ref.indexOf("search.yahoo") > 0) || (ref.indexOf("sharesoutstandinghistory.com") > 0) || (ref.indexOf("marketcaphistory.com") > 0) || (ref.indexOf("ytdreturn.com") > 0) || (ref.indexOf("averageannualreturn.com") > 0) || (ref.indexOf("redinews.com") > 0) || (ref.indexOf("technicalanalysischannel.com") > 0) || (ref.indexOf("stockdma.com") > 0) || (ref.indexOf("stockrsi.com") > 0) || (ref.indexOf("stockmacd.com") > 0) || (ref.indexOf("topdividends.com") > 0) || (ref.indexOf("monthlydividendpayingstocks.com") > 0) || (ref.indexOf("nextearningsdate.com") > 0) || (ref.indexOf("pastearnings.com") > 0) || (ref.indexOf("historicalperatio.com") > 0) || (ref.indexOf("historicalearnings.com") > 0) || (ref.indexOf("webcache.googleusercontent.com") > 0)) { allow = 1; } function ShowTTIPage() { if (allow) { document.write('\n'); } if (allow) { document.write('

\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('
3/19 - 8:17 AM \; \;Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
1/26 - 8:31 AM \; \;Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
1/22 - 8:01 AM \; \;Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002
1/2 - 8:01 AM \; \;Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024
\n'); } if (!allow) { document.write(''+ ''+ '

Access Denied

'+ '

Please Read This Important Message

'+ ' If you are a paying TickerTech.com client and your account was not set up to include the configuration'+ ' received, please email support@tickertech.com,'+ ' or call us at 1-866-515-2082 to verify your account settings.'+ ' '+ '

'+ ' '+ ' Note! If you reached this page'+ ' after attempting to place a TickerTech.com product onto your web page, go no further; you must sign up as a'+ ' paying client. For pricing information please visit our products page, email '+ ' services@tickertech.com, or give us a call at 1-866-515-2082.'+ ' '+ '

'+ ' '+ ' TickerTech.com home
'+ ' TickerTech.com products'+ '
'+ ' '+ ''); } }